|
Fusion gene ID: 30612 |
FusionGeneSummary for RB1_HTR2C |
Fusion gene summary |
Fusion gene information | Fusion gene name: RB1_HTR2C | Fusion gene ID: 30612 | Hgene | Tgene | Gene symbol | RB1 | HTR2C | Gene ID | 5925 | 3358 |
Gene name | RB transcriptional corepressor 1 | 5-hydroxytryptamine receptor 2C | |
Synonyms | OSRC|PPP1R130|RB|p105-Rb|pRb|pp110 | 5-HT1C|5-HT2C|5-HTR2C|5HTR2C|HTR1C | |
Cytomap | 13q14.2 | Xq23 | |
Type of gene | protein-coding | protein-coding | |
Description | retinoblastoma-associated proteinGOS563 exon 17 substitution mutation causes premature stopexon 17 tumor GOS561 substitution mutation causes premature stopprepro-retinoblastoma-associated proteinprotein phosphatase 1, regulatory subunit 130retinoblas | 5-hydroxytryptamine receptor 2C5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled5-hydroxytryptamine receptor 1Cserotonin 5-HT-1C receptorserotonin 5-HT-2C receptor | |
Modification date | 20180523 | 20180523 | |
UniProtAcc | P06400 | P28335 | |
Ensembl transtripts involved in fusion gene | ENST00000267163, ENST00000484879, | ENST00000371951, ENST00000276198, ENST00000371950, | |
Fusion gene scores | * DoF score | 16 X 9 X 8=1152 | 1 X 1 X 1=1 |
# samples | 16 | 1 | |
** MAII score | log2(16/1152*10)=-2.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(1/1*10)=3.32192809488736 | |
Context | PubMed: RB1 [Title/Abstract] AND HTR2C [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation | Oncogene involved fusion gene, in-frame and retained their domain. Tumor suppressor gene involved fusion gene, in-frame but not retained their domain. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | RB1 | GO:0043550 | regulation of lipid kinase activity | 16286473 |
Hgene | RB1 | GO:0045892 | negative regulation of transcription, DNA-templated | 10783144|12065415|19223331 |
Hgene | RB1 | GO:2000679 | positive regulation of transcription regulatory region DNA binding | 25100735 |
Tgene | HTR2C | GO:0006182 | cGMP biosynthetic process | 12970106 |
Tgene | HTR2C | GO:0006874 | cellular calcium ion homeostasis | 19057895 |
Tgene | HTR2C | GO:0007200 | phospholipase C-activating G-protein coupled receptor signaling pathway | 12970106 |
Tgene | HTR2C | GO:0010513 | positive regulation of phosphatidylinositol biosynthetic process | 19057895 |
Tgene | HTR2C | GO:0042493 | response to drug | 18703043 |
Tgene | HTR2C | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 19057895 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | RV | HNSC | TCGA-D6-6827-01A | RB1 | chr13 | 48881542 | + | HTR2C | chrX | 114141152 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000267163 | ENST00000371951 | RB1 | chr13 | 48881542 | + | HTR2C | chrX | 114141152 | + |
In-frame | ENST00000267163 | ENST00000276198 | RB1 | chr13 | 48881542 | + | HTR2C | chrX | 114141152 | + |
Frame-shift | ENST00000267163 | ENST00000371950 | RB1 | chr13 | 48881542 | + | HTR2C | chrX | 114141152 | + |
intron-3CDS | ENST00000484879 | ENST00000371951 | RB1 | chr13 | 48881542 | + | HTR2C | chrX | 114141152 | + |
intron-3CDS | ENST00000484879 | ENST00000276198 | RB1 | chr13 | 48881542 | + | HTR2C | chrX | 114141152 | + |
intron-3CDS | ENST00000484879 | ENST00000371950 | RB1 | chr13 | 48881542 | + | HTR2C | chrX | 114141152 | + |
Top |
FusionProtFeatures for RB1_HTR2C |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
RB1 | HTR2C |
Key regulator of entry into cell division that acts as atumor suppressor. Promotes G0-G1 transition when phosphorylated byCDK3/cyclin-C. Acts as a transcription repressor of E2F1 targetgenes. The underphosphorylated, active form of RB1 interacts withE2F1 and represses its transcription activity, leading to cellcycle arrest. Directly involved in heterochromatin formation bymaintaining overall chromatin structure and, in particular, thatof constitutive heterochromatin by stabilizing histonemethylation. Recruits and targets histone methyltransferasesSUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptionalrepression. Controls histone H4 'Lys-20' trimethylation. Inhibitsthe intrinsic kinase activity of TAF1. Mediates transcriptionalrepression by SMARCA4/BRG1 by recruiting a histone deacetylase(HDAC) complex to the c-FOS promoter. In resting neurons,transcription of the c-FOS promoter is inhibited by BRG1-dependentrecruitment of a phospho-RB1-HDAC1 repressor complex. Upon calciuminflux, RB1 is dephosphorylated by calcineurin, which leads torelease of the repressor complex (By similarity). In case of viralinfections, interactions with SV40 large T antigen, HPV E7 proteinor adenovirus E1A protein induce the disassembly of RB1-E2F1complex thereby disrupting RB1's activity. {ECO:0000250,ECO:0000269|PubMed:15084261}. | G-protein coupled receptor for 5-hydroxytryptamine(serotonin). Also functions as a receptor for various drugs andpsychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic aciddiethylamide (LSD). Ligand binding causes a conformation changethat triggers signaling via guanine nucleotide-binding proteins (Gproteins) and modulates the activity of down-stream effectors.Beta-arrestin family members inhibit signaling via G proteins andmediate activation of alternative signaling pathways. Signalingactivates a phosphatidylinositol-calcium second messenger systemthat modulates the activity of phosphatidylinositol 3-kinase anddown-stream signaling cascades and promotes the release of Ca(2+)ions from intracellular stores. Regulates neuronal activity viathe activation of short transient receptor potential calciumchannels in the brain, and thereby modulates the activation ofpro-opiomelacortin neurons and the release of CRH that thenregulates the release of corticosterone. Plays a role in theregulation of appetite and eating behavior, responses toanxiogenic stimuli and stress. Plays a role in insulin sensitivityand glucose homeostasis. {ECO:0000269|PubMed:12970106,ECO:0000269|PubMed:18703043, ECO:0000269|PubMed:19057895,ECO:0000269|PubMed:7895773}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | RB1 | chr13:48881542 | chrX:114141152 | ENST00000267163 | + | 2 | 27 | 10_18 | 88 | 929 | Compositional bias | Note=Poly-Ala |
Hgene | RB1 | chr13:48881542 | chrX:114141152 | ENST00000267163 | + | 2 | 27 | 20_29 | 88 | 929 | Compositional bias | Note=Poly-Pro |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 364_368 | 183 | 459 | Motif | NPxxY motif%3B important for ligand-induced conformation changes and signaling |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 456_458 | 183 | 459 | Motif | Note=PDZ-binding |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 151_153 | 151 | 249 | Motif | DRY motif%3B important for ligand-induced conformation changes |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 364_368 | 151 | 249 | Motif | NPxxY motif%3B important for ligand-induced conformation changes and signaling |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 456_458 | 151 | 249 | Motif | Note=PDZ-binding |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 364_368 | 183 | 459 | Motif | NPxxY motif%3B important for ligand-induced conformation changes and signaling |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 456_458 | 183 | 459 | Motif | Note=PDZ-binding |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 324_328 | 183 | 459 | Region | Agonist binding |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 324_328 | 151 | 249 | Region | Agonist binding |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 324_328 | 183 | 459 | Region | Agonist binding |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 194_213 | 183 | 459 | Topological domain | Extracellular |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 236_311 | 183 | 459 | Topological domain | Cytoplasmic |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 334_348 | 183 | 459 | Topological domain | Extracellular |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 372_458 | 183 | 459 | Topological domain | Cytoplasmic |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 151_170 | 151 | 249 | Topological domain | Cytoplasmic |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 194_213 | 151 | 249 | Topological domain | Extracellular |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 236_311 | 151 | 249 | Topological domain | Cytoplasmic |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 334_348 | 151 | 249 | Topological domain | Extracellular |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 372_458 | 151 | 249 | Topological domain | Cytoplasmic |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 194_213 | 183 | 459 | Topological domain | Extracellular |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 236_311 | 183 | 459 | Topological domain | Cytoplasmic |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 334_348 | 183 | 459 | Topological domain | Extracellular |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 372_458 | 183 | 459 | Topological domain | Cytoplasmic |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 214_235 | 183 | 459 | Transmembrane | Helical%3B Name%3D5 |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 312_333 | 183 | 459 | Transmembrane | Helical%3B Name%3D6 |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 349_371 | 183 | 459 | Transmembrane | Helical%3B Name%3D7 |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 171_193 | 151 | 249 | Transmembrane | Helical%3B Name%3D4 |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 214_235 | 151 | 249 | Transmembrane | Helical%3B Name%3D5 |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 312_333 | 151 | 249 | Transmembrane | Helical%3B Name%3D6 |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 349_371 | 151 | 249 | Transmembrane | Helical%3B Name%3D7 |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 214_235 | 183 | 459 | Transmembrane | Helical%3B Name%3D5 |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 312_333 | 183 | 459 | Transmembrane | Helical%3B Name%3D6 |
Tgene | >HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 349_371 | 183 | 459 | Transmembrane | Helical%3B Name%3D7 |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | >RB1 | chr13:48881542 | chrX:114141152 | ENST00000267163 | + | 2 | 27 | 870_876 | 88 | 929 | Motif | Nuclear localization signal |
Hgene | >RB1 | chr13:48881542 | chrX:114141152 | ENST00000267163 | + | 2 | 27 | 373_579 | 88 | 929 | Region | Note=Domain A |
Hgene | >RB1 | chr13:48881542 | chrX:114141152 | ENST00000267163 | + | 2 | 27 | 373_771 | 88 | 929 | Region | Note=Pocket%3B binds T and E1A |
Hgene | >RB1 | chr13:48881542 | chrX:114141152 | ENST00000267163 | + | 2 | 27 | 580_639 | 88 | 929 | Region | Note=Spacer |
Hgene | >RB1 | chr13:48881542 | chrX:114141152 | ENST00000267163 | + | 2 | 27 | 640_771 | 88 | 929 | Region | Note=Domain B |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 151_153 | 183 | 459 | Motif | DRY motif%3B important for ligand-induced conformation changes |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 151_153 | 183 | 459 | Motif | DRY motif%3B important for ligand-induced conformation changes |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 134_139 | 183 | 459 | Region | Agonist binding |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 134_139 | 151 | 249 | Region | Agonist binding |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 134_139 | 183 | 459 | Region | Agonist binding |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 111_127 | 183 | 459 | Topological domain | Extracellular |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 151_170 | 183 | 459 | Topological domain | Cytoplasmic |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 33_52 | 183 | 459 | Topological domain | Extracellular |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 79_89 | 183 | 459 | Topological domain | Cytoplasmic |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 111_127 | 151 | 249 | Topological domain | Extracellular |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 33_52 | 151 | 249 | Topological domain | Extracellular |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 79_89 | 151 | 249 | Topological domain | Cytoplasmic |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 111_127 | 183 | 459 | Topological domain | Extracellular |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 151_170 | 183 | 459 | Topological domain | Cytoplasmic |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 33_52 | 183 | 459 | Topological domain | Extracellular |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 79_89 | 183 | 459 | Topological domain | Cytoplasmic |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 128_150 | 183 | 459 | Transmembrane | Helical%3B Name%3D3 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 171_193 | 183 | 459 | Transmembrane | Helical%3B Name%3D4 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 53_78 | 183 | 459 | Transmembrane | Helical%3B Name%3D1 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000276198 | + | 4 | 6 | 90_110 | 183 | 459 | Transmembrane | Helical%3B Name%3D2 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 128_150 | 151 | 249 | Transmembrane | Helical%3B Name%3D3 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 53_78 | 151 | 249 | Transmembrane | Helical%3B Name%3D1 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371950 | + | 4 | 6 | 90_110 | 151 | 249 | Transmembrane | Helical%3B Name%3D2 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 128_150 | 183 | 459 | Transmembrane | Helical%3B Name%3D3 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 171_193 | 183 | 459 | Transmembrane | Helical%3B Name%3D4 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 53_78 | 183 | 459 | Transmembrane | Helical%3B Name%3D1 |
Tgene | HTR2C | chr13:48881542 | chrX:114141152 | ENST00000371951 | + | 5 | 7 | 90_110 | 183 | 459 | Transmembrane | Helical%3B Name%3D2 |
Top |
FusionGeneSequence for RB1_HTR2C |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
>In-frame_RB1_ENST00000267163_chr13_48881542_+_HTR2C_ENST00000371951_chrX_114141152_+_363aa MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLVY QFLSLXLDXGTKKRCSXTTRRACSTTQISFLLGPSXLSSYRXRLWXLRIAXPSTFCADKLXCYCTATPRNRLDXVWISXSAARGIRPRKR TLQTLTKTRTHAEERRRRDVLGAPCRLSTMKEKLRKSLGLFSLCFXSCGAHFSLPIFCLFFVRSPVTKSSWKSFXMCLFGLAMFVQESIL WCILCSTKFTEGHSPTICVAIIRXRKSLLSGRFQELPPLLCLGGSLMLTFIGIPMNRXSRKPVTMSPVXRCKLRIXSYQXIPPVWLAKGL >In-frame_RB1_ENST00000267163_chr13_48881542_+_HTR2C_ENST00000276198_chrX_114141152_+_363aa MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLVY QFLSLXLDXGTKKRCSXTTRRACSTTQISFLLGPSXLSSYRXRLWXLRIAXPSTFCADKLXCYCTATPRNRLDXVWISXSAARGIRPRKR TLQTLTKTRTHAEERRRRDVLGAPCRLSTMKEKLRKSLGLFSLCFXSCGAHFSLPIFCLFFVRSPVTKSSWKSFXMCLFGLAMFVQESIL WCILCSTKFTEGHSPTICVAIIRXRKSLLSGRFQELPPLLCLGGSLMLTFIGIPMNRXSRKPVTMSPVXRCKLRIXSYQXIPPVWLAKGL |
* Fusion transcript sequences (only coding sequence (CDS) region). |
>In-frame_RB1_ENST00000267163_chr13_48881542_+_HTR2C_ENST00000371951_chrX_114141152_+_1091nt ATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCGCTGCCGCCGCGGAACCCCCGGCACCGCCGCCGCCGCCCCCTCCTGAG GAGGACCCAGAGCAGGACAGCGGCCCGGAGGACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTA TGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCTTGGTTAACTTGGGAGAAAGTTTCATCTGTGGATGGAGTATTGGTGTAT CAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGGTGTTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTC TTATTGGGTCCTTCGTAGCTTTCTTCATACCGCTGACGATTATGGTGATTACGTATTGCCTGACCATCTACGTTCTGCGCCGACAAGCTT TGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAAGTCTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGA ACTCTGCAAACCCTAACCAAGACCAGAACGCACGCCGAAGAAAGAAGAAGGAGAGACGTCCTAGGGGCACCATGCAGGCTATCAACAATG AAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGTTTCTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTC TTTGTGAGAAGTCCTGTAACCAAAAGCTCATGGAAAAGCTTCTGAATGTGTTTGTTTGGATTGGCTATGTTTGTTCAGGAATCAATCCTC TGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCTCCAACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCA GGCAGATTCCAAGAGTTGCCGCCACTGCTTTGTCTGGGAGGGAGCTTAATGTTAACATTTATCGGCATACCAATGAACCGGTGATCGAGA AAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGAATTTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTA >In-frame_RB1_ENST00000267163_chr13_48881542_+_HTR2C_ENST00000276198_chrX_114141152_+_1091nt ATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCGCTGCCGCCGCGGAACCCCCGGCACCGCCGCCGCCGCCCCCTCCTGAG GAGGACCCAGAGCAGGACAGCGGCCCGGAGGACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTA TGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCTTGGTTAACTTGGGAGAAAGTTTCATCTGTGGATGGAGTATTGGTGTAT CAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGGTGTTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTC TTATTGGGTCCTTCGTAGCTTTCTTCATACCGCTGACGATTATGGTGATTACGTATTGCCTGACCATCTACGTTCTGCGCCGACAAGCTT TGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAAGTCTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGA ACTCTGCAAACCCTAACCAAGACCAGAACGCACGCCGAAGAAAGAAGAAGGAGAGACGTCCTAGGGGCACCATGCAGGCTATCAACAATG AAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGTTTCTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTC TTTGTGAGAAGTCCTGTAACCAAAAGCTCATGGAAAAGCTTCTGAATGTGTTTGTTTGGATTGGCTATGTTTGTTCAGGAATCAATCCTC TGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCTCCAACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCA GGCAGATTCCAAGAGTTGCCGCCACTGCTTTGTCTGGGAGGGAGCTTAATGTTAACATTTATCGGCATACCAATGAACCGGTGATCGAGA AAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGAATTTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTA |
* Fusion transcript sequences (Full-length transcript). |
>In-frame_RB1_ENST00000267163_chr13_48881542_+_HTR2C_ENST00000371951_chrX_114141152_+_2321nt TCCGGTTTTTCTCAGGGGACGTTGAAATTATTTTTGTAACGGGAGTCGGGAGAGGACGGGGCGTGCCCCGACGTGCGCGCGCGTCGTCCT CCCCGGCGCTCCTCCACAGCTCGCTGGCTCCCGCCGCGGAAAGGCGTCATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCC GCTGCCGCCGCGGAACCCCCGGCACCGCCGCCGCCGCCCCCTCCTGAGGAGGACCCAGAGCAGGACAGCGGCCCGGAGGACCTGCCTCTC GTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTATGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCT TGGTTAACTTGGGAGAAAGTTTCATCTGTGGATGGAGTATTGGTGTATCAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGG TGTTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTCTTATTGGGTCCTTCGTAGCTTTCTTCATACCGCTGACGATTA TGGTGATTACGTATTGCCTGACCATCTACGTTCTGCGCCGACAAGCTTTGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAA GTCTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGAACTCTGCAAACCCTAACCAAGACCAGAACGCACGCCGAAGAA AGAAGAAGGAGAGACGTCCTAGGGGCACCATGCAGGCTATCAACAATGAAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGT TTCTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTCTTTGTGAGAAGTCCTGTAACCAAAAGCTCATGGAAAAGCTTC TGAATGTGTTTGTTTGGATTGGCTATGTTTGTTCAGGAATCAATCCTCTGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCT CCAACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCAGGCAGATTCCAAGAGTTGCCGCCACTGCTTTGTCTGGGAGGG AGCTTAATGTTAACATTTATCGGCATACCAATGAACCGGTGATCGAGAAAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGA ATTTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTAGCAGTGTGTGAGAAAGAACAGCACAGTCTTTTCCTACGGTAC AAGCTACATATGTAGGAAAATTTTCTTCTTTAATTTTTCTGTTGGTCTTAACTAATGTAAATATTGCTGTCTGAAAAAGTGTTTTTACAT ATAGCTTTGCAACCTTGTACTTTACAATCATGCCTACATTAGTGAGATTTAGGGTTCTATATTTACTGTTTATAATAGGTGGAGACTAAC TTATTTTGATTGTTTGATGAATAAAATGTTTATTTTTGCTCTCCCTCCCTTCTTTCCTTCCTTTTTTCCTTTCTTCCTTCCTTTCTCTCT TTCTTTTGTGCATATGGCAACGTTCATGTTCATCTCAGGTGGCATTTGCAGGTGACCAGAATGAGGCACATGACAGTGGTTATATTTCAA CCACACCTAAATTAACAAATTCAGTGGACATTTGTTCTGGGTTAACAGTAAATATACACTTTACATTCTTGCTCTGCTCATCTACACATA TAAACACAGTAAGATAGGTTCTGCTTTCTGATACATCTGTCAGTGAGTCAGAGGCAGAACCTAGTCTTGTTGTTCATATAGGGGCAAAAA TTTGACATTGTCAGAATGTTGTGTTGGTATTTACTGCAATGTCTGTCCCTAAACATAGTGGTATTTTAACATAGCAGCTGGTTAACCGGG ACTACAGAAGTGGAAGGATAATGAGATGTAATACACCAAATAGCTTTTCACTTCTTAAGGACAGTGTTCAAATTCTGATTATTACAACAA GCAAACTGAAATTAGTGTTTTCATTCTGGTCCTTAGTAAATTCCTAATTCTATGATTAAACTGGGAAATGAGATCCCAGAGTTATTTCCC AACCCAGGATTCAACATCAATTGGGTTTTGATCTCAGCATCCTGGAAATTTGTGTGCTTCACACAAAGTGAAATTAGTATTTTGAGCCTT ATTAAAATATTTTCTTAATTATGGTACCTCTGTCTATAGGACTTAATTTAGCAGTCCATTTTTGAGTAAAACTTGTATTGGAAGTATAGA >In-frame_RB1_ENST00000267163_chr13_48881542_+_HTR2C_ENST00000276198_chrX_114141152_+_3875nt TCCGGTTTTTCTCAGGGGACGTTGAAATTATTTTTGTAACGGGAGTCGGGAGAGGACGGGGCGTGCCCCGACGTGCGCGCGCGTCGTCCT CCCCGGCGCTCCTCCACAGCTCGCTGGCTCCCGCCGCGGAAAGGCGTCATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCC GCTGCCGCCGCGGAACCCCCGGCACCGCCGCCGCCGCCCCCTCCTGAGGAGGACCCAGAGCAGGACAGCGGCCCGGAGGACCTGCCTCTC GTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTATGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCT TGGTTAACTTGGGAGAAAGTTTCATCTGTGGATGGAGTATTGGTGTATCAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGG TGTTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTCTTATTGGGTCCTTCGTAGCTTTCTTCATACCGCTGACGATTA TGGTGATTACGTATTGCCTGACCATCTACGTTCTGCGCCGACAAGCTTTGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAA GTCTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGAACTCTGCAAACCCTAACCAAGACCAGAACGCACGCCGAAGAA AGAAGAAGGAGAGACGTCCTAGGGGCACCATGCAGGCTATCAACAATGAAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGT TTCTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTCTTTGTGAGAAGTCCTGTAACCAAAAGCTCATGGAAAAGCTTC TGAATGTGTTTGTTTGGATTGGCTATGTTTGTTCAGGAATCAATCCTCTGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCT CCAACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCAGGCAGATTCCAAGAGTTGCCGCCACTGCTTTGTCTGGGAGGG AGCTTAATGTTAACATTTATCGGCATACCAATGAACCGGTGATCGAGAAAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGA ATTTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTAGCAGTGTGTGAGAAAGAACAGCACAGTCTTTTCCTACGGTAC AAGCTACATATGTAGGAAAATTTTCTTCTTTAATTTTTCTGTTGGTCTTAACTAATGTAAATATTGCTGTCTGAAAAAGTGTTTTTACAT ATAGCTTTGCAACCTTGTACTTTACAATCATGCCTACATTAGTGAGATTTAGGGTTCTATATTTACTGTTTATAATAGGTGGAGACTAAC TTATTTTGATTGTTTGATGAATAAAATGTTTATTTTTGCTCTCCCTCCCTTCTTTCCTTCCTTTTTTCCTTTCTTCCTTCCTTTCTCTCT TTCTTTTGTGCATATGGCAACGTTCATGTTCATCTCAGGTGGCATTTGCAGGTGACCAGAATGAGGCACATGACAGTGGTTATATTTCAA CCACACCTAAATTAACAAATTCAGTGGACATTTGTTCTGGGTTAACAGTAAATATACACTTTACATTCTTGCTCTGCTCATCTACACATA TAAACACAGTAAGATAGGTTCTGCTTTCTGATACATCTGTCAGTGAGTCAGAGGCAGAACCTAGTCTTGTTGTTCATATAGGGGCAAAAA TTTGACATTGTCAGAATGTTGTGTTGGTATTTACTGCAATGTCTGTCCCTAAACATAGTGGTATTTTAACATAGCAGCTGGTTAACCGGG ACTACAGAAGTGGAAGGATAATGAGATGTAATACACCAAATAGCTTTTCACTTCTTAAGGACAGTGTTCAAATTCTGATTATTACAACAA GCAAACTGAAATTAGTGTTTTCATTCTGGTCCTTAGTAAATTCCTAATTCTATGATTAAACTGGGAAATGAGATCCCAGAGTTATTTCCC AACCCAGGATTCAACATCAATTGGGTTTTGATCTCAGCATCCTGGAAATTTGTGTGCTTCACACAAAGTGAAATTAGTATTTTGAGCCTT ATTAAAATATTTTCTTAATTATGGTACCTCTGTCTATAGGACTTAATTTAGCAGTCCATTTTTGAGTAAAACTTGTATTGGAAGTATAGA TGGTAGAAACTTTGGAAGTTTTACTTGATTAAGGACTACAGAATTGGGCCCTTAGAATGTGAAAAAAAAAAGTAATTAAAAAGACACTTT TACCGAACTCGGGATTACAGAAACACGGAGTTTCCATTTGGATTTTAAACAAAATTTATGTCATTTTCAGATCCTTCCAAACTCTCTAGT GCAGGAAAAGGCTGCAGCTAATTTGTGAAAGTGGCAAGCTCTTCATTGCACTGCAGTTATTTACCAGAAGTTTAAATCTTTGTTAAAATA TAGTGTTGTGTTACAATAAGTGTTGGCCATCATTTCATTCGTGGGCCTGCTGCTCTCTAAGAATTCAGTAGCATTTTAATAGTTTCTAAA CCATGAAAAGTTTTCAAGCATTGCTAAAGTCAGGCCATTCAGTCTATGCTGTGTGCAGAGTATACAAGTGTTTCTAGTAACAGTATTTCC ATACGTGCCCATTTCACACAACTGTGGATAAATTTTGGAAGAATTCATGATGCTAGTTCTTACGCTTGACAGTTACTTACACACCTGAGA ATGTGCCTCTCAGTATCTTAAAATTGGTTAATGAAAAATCTGAATTTCTAAAACCCTTGGTCTGTGTTCTCAACACACAGTATAGATAAA TCCAATAGTCTGCCACAAGGGCAGTGGAAGAGCTGCTGTATTTGAGGAAACTCATACAGTCTCTATTTGATTTGCAACACTGCCAAACAT CAGTCAATTGCTTGAGCATGCCCAAATATAACATGAAAGTCAAGTCTACCTGCCTTGCCTGTTAGGTCTGTTGAAGTGCATGTTAAAATA ATTATATGAAGCAGAATGAGATGATTTAATTCTTACCGAAATGAAAATGGCTGAAGAAACACAGCATGCATTTAGCATGAGTTCTGCACA TACAGATGGTGTCCTGCATGTATGCCATGTATGTTGCATGAATCCATCGATTTGTATTAATGTAGGGCAGAATAGCTGATAGAAGAAGGA CTGAAGAAAATCCTTCAGCAATCCTTAAAAAGACCATGCATTCAGATCTGAAGTAGTGTGAGTGTTAGAAAAAACTGGAAACATCTGATT TCTGAACTATCAGGGCAAGCTCATAGCACATGTTTTACAAAGAAACAAAATATAAATCACAGATTTCCAAAAGTACTAGCAATAAGTTGA ATGATAATAGCTCACAGCACATTTGTTAATGATTCTTGTGTCATCAAGTAGTAGTACTTAATAGTACCCAACCTGGTAATTATCCTCAAG TTGTGTGCTATTCGTAAGTTCTGTGCAGTTTGGTATGAAACAAATATACTCATTTGGATATAAATCTTACCCTTCAATGTTAAATCTACA AACTTTTATAAATGTTTTAAAGAAGTCCATGTGATAATTGTAAAGGTGATGAATTTACCATCAAACAAATCATTTTGATGTATTATTATA TATGTATATCTGTGTAAGACACGTGCAACAGACTGCCTTATATTATTTTCTGTAATTCTTCTCCTTTGTCAAATGGTATTTTTTGTGAAT GGTTGCAAAGTGTTGTCTTATTCCTAATTCCTGTATGTTATCCACTACAGGTTTTATGAGACTTCCTATTAATTTATTAAATTTATTAAA |
Top |
FusionGenePPI for RB1_HTR2C |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
RB1 | CUX1, MCM7, HBP1, TRAP1, AATF, THOC1, LIN9, BRCA1, ABL1, BCR, NCOA6, BAG1, RBBP8, HDAC1, AR, MORF4L2, SERPINB2, TP73, GNB2L1, CBX1, PELP1, PIK3R3, PPARG, HDAC3, RBBP4, E2F1, MORF4L1, MRFAP1, RBBP7, CDK2, DNMT1, HDAC2, ARID4A, NFIX, SP1, SMARCA4, MYOD1, DNMT3A, EID1, BRF1, PRDM2, SUV39H1, CBX5, CBX4, RING1, VDR, KDM5A, CCND3, PML, CCND1, TAF1, PA2G4, TMPO, MYC, TGM2, POLA1, FRK, ATF2, SNW1, ARID3B, SNAPC1, SNAPC3, CCNT2, CDK9, RAF1, E2F4, E4F1, ENC1, RFC1, LMNA, CREG1, CEBPB, HMGB1, PHB, MDM2, JUN, PAX6, MNAT1, RBBP5, E2F2, TRIP11, UBTF, AHR, ARNT, CCNA1, TFDP1, TFDP2, RBBP9, TBP, USP4, L3MBTL1, L3MBTL2, AURKB, CDK4, ZBTB7A, SKP2, HMGA2, KDM5B, KDM4A, STAT3, KDM1A, LIN54, SKI, SKIL, KAT2B, FOXM1, YY1, DNAJA2, SMYD2, UHRF2, TAL1, TCF3, LMO2, LDB1, IRF3, NPM1, CEBPA, KAT5, TRIM27, CCNE1, CDK5, CCND2, PSMA7, CCNA2, CDK1, PSMD10, CDC27, ANAPC2, CDC16, FZR1, MAPK14, TP53, PPP1CA, CDK6, RNF40, UHRF1, UBR4, RBAK, SPI1, E2F3, CHEK2, CHEK1, CEBPD, MDM4, PAX2, PNO1, GTF2H1, PURA, CCNB1, RINT1, FOS, CDK14, PPIA, TOP2A, NOTCH1, RUNX2, ID2, CDK3, DGKZ, INS, HIST4H4, PRMT2, CASP3, CASP6, CASP7, CASP8, CASP9, CASP10, MAPK8, UBE2I, CEBPE, MRPS18B, CCNC, PRKCB, TFAP2A, PAX5, HIF1A, CDKN1A, CDKN1C, HDAC11, PLA2G12A, MAGEA11, NEFM, DYRK1A, DYRK1B, USP7, KDM2A, EP300, SIRT1, PAX8, KLK11, RFPL2, FAS, TFDP3, CTBP1, C3orf62, CDK13, NTRK1, RBBP6, GTF3C2, GRB2, RABGAP1L, CHN2, ANKS1A, CLNK, MED23, BAG6, UBL4A, HERC4, RPRD1B, RBM26, FOXA3, FOXK1, FOXK2, FOXO1, FOXO3, PPP1R26, NFATC2, BRD4, FAM208A, RFC5, PPAN, KIAA0430, HELZ, PCGF3, HSP90AA1, WEE1, TUBA1A | HTR2C | MPDZ, DLG4, LIN7C, APBA1, CALM1, SNTA1, TAPBP, FAM134A, KLRG2, CERS5, SLC35F1, FAM210B, UBE2Q1, C6orf47, HMOX2, ITPRIPL1, FAM134C, GPR50, LPCAT3, ARL10, PDXDC1, RBM14-RBM4, KNTC1, TMEM147, ITPA, ATP8, CERS6, CAV1, XPO7, IPO11, LGALS3, SLC35G2, ACP2, FITM2, ATP2B2, SLC39A1, LMBRD2, NT5C3A, EFR3A, GOLGA5, HEATR3, DPY19L4, SEC63, PDS5B, BTAF1, ALG8, TNPO3, RTN4, TBC1D15, RMND1, SLC19A2, SLC35F2, TVP23C, ATP5B, PTRH2, CAND2, CERS2, GPR89A, IPO9, LRRC8A, GLMN, ACTA2, RINT1, EXTL3, NCAPG, TM9SF3, SERINC1, FADS1, MRS2, IPO7, MBOAT7, ANGEL1, TMPPE, NCAPD2, KIAA0368, KIAA1524, SFXN5, C10orf35, TNPO2, ALG10, CAND1, C19orf25, MTX1, SYNGR2, GPRC5C, ASPH, ATP5F1, GNB2, EIF2B3 |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Hgene | RB1 | chr13:48881542 | chrX:114141152 | ENST00000267163 | + | 2 | 27 | 763_928 | 88 | 929 | LIMD1 |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for RB1_HTR2C |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | RB1 | P06400 | DB00071 | Insulin Pork | Retinoblastoma-associated protein | biotech | approved |
Hgene | RB1 | P06400 | DB00030 | Insulin Human | Retinoblastoma-associated protein | biotech | approved|investigational |
Tgene | HTR2C | P28335 | DB00215 | Citalopram | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00246 | Ziprasidone | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00247 | Methysergide | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00248 | Cabergoline | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00321 | Amitriptyline | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00363 | Clozapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00370 | Mirtazapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00408 | Loxapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00434 | Cyproheptadine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00458 | Imipramine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00540 | Nortriptyline | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00543 | Amoxapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00623 | Fluphenazine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00696 | Ergotamine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00726 | Trimipramine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00777 | Propiomazine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00805 | Minaprine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB01224 | Quetiapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB01267 | Paliperidone | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB04871 | Lorcaserin | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB06216 | Asenapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
Tgene | HTR2C | P28335 | DB00574 | Fenfluramine | 5-hydroxytryptamine receptor 2C | small molecule | approved|illicit|investigational|withdrawn |
Tgene | HTR2C | P28335 | DB01191 | Dexfenfluramine | 5-hydroxytryptamine receptor 2C | small molecule | approved|illicit|investigational|withdrawn |
Tgene | HTR2C | P28335 | DB00193 | Tramadol | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB00268 | Ropinirole | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB00334 | Olanzapine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB00413 | Pramipexole | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB00589 | Lisuride | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB00656 | Trazodone | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB00714 | Apomorphine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB00734 | Risperidone | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB00934 | Maprotiline | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB01142 | Doxepin | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB01151 | Desipramine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB01200 | Bromocriptine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB01238 | Aripiprazole | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB01403 | Methotrimeprazine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB06148 | Mianserin | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB06594 | Agomelatine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB09014 | Captodiame | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
Tgene | HTR2C | P28335 | DB00477 | Chlorpromazine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|vet_approved |
Tgene | HTR2C | P28335 | DB01242 | Clomipramine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|vet_approved |
Tgene | HTR2C | P28335 | DB01392 | Yohimbine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|vet_approved |
Tgene | HTR2C | P28335 | DB01186 | Pergolide | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|vet_approved|withdrawn |
Tgene | HTR2C | P28335 | DB01079 | Tegaserod | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|withdrawn |
Tgene | HTR2C | P28335 | DB01239 | Chlorprothixene | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|withdrawn |
Tgene | HTR2C | P28335 | DB06144 | Sertindole | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|withdrawn |
Tgene | HTR2C | P28335 | DB00420 | Promazine | 5-hydroxytryptamine receptor 2C | small molecule | approved|vet_approved |
Tgene | HTR2C | P28335 | DB00472 | Fluoxetine | 5-hydroxytryptamine receptor 2C | small molecule | approved|vet_approved |
Tgene | HTR2C | P28335 | DB01149 | Nefazodone | 5-hydroxytryptamine receptor 2C | small molecule | approved|withdrawn |
Top |
RelatedDiseases for RB1_HTR2C |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | RB1 | C0035335 | Retinoblastoma | 9 | CTD_human;HPO;UNIPROT |
Hgene | RB1 | C1458155 | Mammary Neoplasms | 3 | CTD_human |
Hgene | RB1 | C0149925 | Small cell carcinoma of lung | 2 | CTD_human;ORPHANET |
Hgene | RB1 | C2239176 | Liver carcinoma | 2 | CTD_human |
Hgene | RB1 | C0001624 | Adrenal Gland Neoplasms | 1 | CTD_human |
Hgene | RB1 | C0007117 | Basal cell carcinoma | 1 | CTD_human |
Hgene | RB1 | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
Hgene | RB1 | C0007786 | Brain Ischemia | 1 | CTD_human |
Hgene | RB1 | C0023904 | Liver Neoplasms, Experimental | 1 | CTD_human |
Hgene | RB1 | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
Hgene | RB1 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
Hgene | RB1 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
Hgene | RB1 | C0027659 | Neoplasms, Experimental | 1 | CTD_human |
Hgene | RB1 | C0029463 | Osteosarcoma | 1 | CTD_human;HPO |
Hgene | RB1 | C0030297 | Pancreatic Neoplasm | 1 | CTD_human |
Hgene | RB1 | C0036920 | Sezary Syndrome | 1 | CTD_human |
Hgene | RB1 | C0038325 | Stevens-Johnson Syndrome | 1 | CTD_human |
Hgene | RB1 | C0206686 | Adrenocortical carcinoma | 1 | CTD_human |
Hgene | RB1 | C0279626 | Squamous cell carcinoma of esophagus | 1 | CTD_human |
Hgene | RB1 | C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1 | CTD_human |
Tgene | HTR2C | C0001973 | Alcoholic Intoxication, Chronic | 5 | PSYGENET |
Tgene | HTR2C | C0005586 | Bipolar Disorder | 5 | PSYGENET |
Tgene | HTR2C | C0011570 | Mental Depression | 5 | PSYGENET |
Tgene | HTR2C | C0011581 | Depressive disorder | 5 | PSYGENET |
Tgene | HTR2C | C0041696 | Unipolar Depression | 5 | PSYGENET |
Tgene | HTR2C | C0525045 | Mood Disorders | 5 | PSYGENET |
Tgene | HTR2C | C1269683 | Major Depressive Disorder | 5 | PSYGENET |
Tgene | HTR2C | C0036341 | Schizophrenia | 4 | PSYGENET |
Tgene | HTR2C | C0524620 | Metabolic Syndrome X | 3 | CTD_human |
Tgene | HTR2C | C0028754 | Obesity | 2 | CTD_human |
Tgene | HTR2C | C0043094 | Weight Gain | 2 | CTD_human |
Tgene | HTR2C | C0085159 | Seasonal Affective Disorder | 2 | PSYGENET |
Tgene | HTR2C | C0009171 | Cocaine Abuse | 1 | PSYGENET |
Tgene | HTR2C | C0038587 | Substance Withdrawal Syndrome | 1 | CTD_human |
Tgene | HTR2C | C0424295 | Hyperactive behavior | 1 | CTD_human |